Clinical trial · Interventional
Study of XL999 in Patients With Non-small Cell Lung Cancer
A Phase 2 Study of XL999 Administered Intravenously to Subjects With Non-Small-Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study was terminated due to cardiac toxicities in the subejcts
Summary
Brief summary (as posted)
This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with non-small cell lung cancer (NSCLC). XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| XL999 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Response rate
- timeFrame
- Inclusion until disease progression
- measure
- Safety and tolerability
- timeFrame
- Inclusion until 30 dyas post last treatment
Secondary outcomes (4)
- measure
- Progression-free survival
- timeFrame
- Inclusion until disease progression
- measure
- Duration of response
- timeFrame
- Inclusion until disease progression
- measure
- Overall survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Males and females with histologically confirmed NSCLC * Prior treatment with a platinum- or taxane containing regimen * Stage IIIB with malignant effusion, stage IV or recurrent NSCLC that is not amenable to curative therapy (either surgery or radiation therapy) * Measurable disease according to Response Criteria for Solid Tumors (RECIST) * ECOG performance status of 0 or 1 * Life expectancy ≥3 months * Adequate organ and marrow function * No other malignancies within 5 years * Signed informed consent Exclusion Criteria: * Radiation to ≥25% of bone marrow within 30 days of XL999 treatment * Use of any systemic anticancer therapy within 30 days of XL999 treatment * More than 2 prior systemic cytotoxic chemotherapy regimens * More than 1 prior agent targeted against VEGF or EGFR (eg, bevacizumab, erlotinib, or gefitinib) * Subject has not recovered to ≤ grade 1 or to within 10% of baseline from adverse events due to other medications administered \>30 days before study enrollment * Uncontrolled and/or intercurrent illness * History of or known brain metastases, current spinal cord compression, or carcinomatous meningitis * Pregnant or breastfeeding females * Known HIV
References
Publications (0)
Data not yet available